Glucagon-like peptide-1 receptor agonists in diabetic kidney disease: A review of their kidney and heart protection.

Am J Prev Cardiol · 2023 · PMC10258236 · PMID 37313358

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

GLP1-RA showed a trend for benefit with a 14% reduction, which did not meet statistical significance [HR, 0.86 (0.72–1.02)] [26] .

also in 53,322 other papers

a trend toward significanceno p-value reported

In the PIONEER 6 trial (which was designed to rule out an excess in cardiovascular risk with oral semaglutide among patients with T2D and not powered to demonstrate superiority), oral semaglutide demonstrated cardiovascular safety compared with placebo, and although there was a trend toward significance for benefit (eg, a 21% risk reduction), statistical significance was not met [43] .

also in 3,729 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.